Atea Pharmaceuticals, Inc. (AVIR) Operating income 2018–2025
Atea Pharmaceuticals, Inc. (AVIR) annual operating income history from SEC filings — each fiscal year as reported.
-$180.9MFY2025 · since FY2018: -$9.5M → -$180.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$180.9M | +6.3% |
| FY2024 | -$192.9M | -17.5% |
| FY2023 | -$164.2M | -25.7% |
| FY2022 | -$130.7M | -194.4% |
| FY2021 | $138.4M | +1354.6% |
| FY2020 | -$11.0M | +24.5% |
| FY2019 | -$14.6M | -54.1% |
| FY2018 | -$9.5M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More AVIR financial trends
AVIR RevenueAVIR Net incomeAVIR Net marginAVIR Gross profitAVIR Gross marginAVIR Operating marginAVIR Operating cash flowAVIR Free cash flowAVIR Capital expendituresAVIR Return on equityAVIR Stock buybacksAVIR Dividends paidAVIR Total assetsAVIR Total liabilitiesAVIR Shareholders’ equityAVIR overview →